Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798730 | 0.85 | NR3C1 (0.46) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22759303 | 0.81 | NR3C1 (0.45) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22759078 | 0.79 | NR3C1 (0.44) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22759304 | 0.79 | NR3C1 (0.42) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546345 | 0.76 | GPR119 (0.42) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546418 | 0.75 | GPR119 (0.42) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL14637282 | 0.75 | STS (0.47) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546379 | 0.75 | GPR119 (0.48) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL24007611 | 0.74 | STS (0.49) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL21217881 | 0.74 | GPR119 (0.44) | GPR119KDM4EMAPTTHRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4166556-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| WO-2020244613-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | 北京泰德制药股份有限公司 | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | NR3C1 1270/4885GPR119 1674/4885KDM4E 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.